SET and MYND domain-containing protein 2 (SMYD2)

SET and MYND domain-containing protein 2 (SMYD2) is a histone lysine methyltransferase belonging to the SMYD family of proteins, characterized by a catalytic SET domain and a MYND-type zinc finger involved in protein-protein interactions. SMYD2 catalyzes methylation of lysine residues on histones (commonly H3K36, H3K4, and H4K20), as well as on various non-histone proteins, affecting diverse cellular processes such as transcriptional regulation, cell differentiation, cell cycle progression, apoptosis, and inflammation. SMYD2 dysregulation is implicated in carcinogenesis, cardiovascular disease (including vascular smooth muscle cell dysfunction and neointimal hyperplasia), and inflammation. Through interaction with factors such as myocardin and p300, SMYD2 plays key roles in controlling gene expression programs relevant to muscle cells, cancer, and vascular biology. Its involvement in disease and cellular processes makes it an emerging therapeutic target for small molecule inhibitors, primarily in preclinical and early research settings. If further detail on drug development or biomarker applications for SMYD2 is desired, additional targeted searches are required, as no approved drugs were identified in the provided results.

Other names

SMYD2KMT3CLysine methyltransferase 3C

Inhibition of lysine methyltransferase activity, possibly affecting both histone and non-histone protein methylation, thereby altering gene expression, cell proliferation, and other cellular processes.